X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs ABBOTT INDIA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD ABBOTT INDIA ALEMBIC LTD/
ABBOTT INDIA
 
P/E (TTM) x 55.9 40.2 139.2% View Chart
P/BV x 2.3 10.3 22.6% View Chart
Dividend Yield % 0.4 0.7 65.4%  

Financials

 ALEMBIC LTD   ABBOTT INDIA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
ABBOTT INDIA
Mar-18
ALEMBIC LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs726,110 1.2%   
Low Rs343,996 0.8%   
Sales per share (Unadj.) Rs4.71,552.2 0.3%  
Earnings per share (Unadj.) Rs6.1188.8 3.2%  
Cash flow per share (Unadj.) Rs6.2196.4 3.2%  
Dividends per share (Unadj.) Rs0.2055.00 0.4%  
Dividend yield (eoy) %0.41.1 34.7%  
Book value per share (Unadj.) Rs40.7796.6 5.1%  
Shares outstanding (eoy) m267.0321.25 1,256.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.33.3 346.0%   
Avg P/E ratio x8.726.8 32.4%  
P/CF ratio (eoy) x8.525.7 33.0%  
Price / Book Value ratio x1.36.3 20.5%  
Dividend payout %3.329.1 11.2%   
Avg Mkt Cap Rs m14,139107,376 13.2%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m2073,937 5.3%   
Avg. sales/employee Rs ThNM9,929.3-  
Avg. wages/employee Rs ThNM1,185.1-  
Avg. net profit/employee Rs ThNM1,207.7-  
INCOME DATA
Net Sales Rs m1,25532,985 3.8%  
Other income Rs m3701,170 31.6%   
Total revenues Rs m1,62534,155 4.8%   
Gross profit Rs m1115,245 2.1%  
Depreciation Rs m38162 23.3%   
Interest Rs m238 4.5%   
Profit before tax Rs m4426,215 7.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m242,203 1.1%   
Profit after tax Rs m1,6304,012 40.6%  
Gross profit margin %8.915.9 55.7%  
Effective tax rate %5.435.4 15.3%   
Net profit margin %129.812.2 1,067.5%  
BALANCE SHEET DATA
Current assets Rs m1,86722,655 8.2%   
Current liabilities Rs m5916,681 8.8%   
Net working cap to sales %101.648.4 209.9%  
Current ratio x3.23.4 93.1%  
Inventory Days Days9465 145.5%  
Debtors Days Days7429 252.3%  
Net fixed assets Rs m1,791835 214.4%   
Share capital Rs m534213 251.3%   
"Free" reserves Rs m10,32416,715 61.8%   
Net worth Rs m10,85816,928 64.1%   
Long term debt Rs m410-   
Total assets Rs m11,59124,162 48.0%  
Interest coverage x260.9163.7 159.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.11.4 7.9%   
Return on assets %14.116.8 84.0%  
Return on equity %15.023.7 63.3%  
Return on capital %15.236.9 41.1%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19369 5.3%   
Fx outflow Rs m2643,807 6.9%   
Net fx Rs m-244-3,438 7.1%   
CASH FLOW
From Operations Rs m2361,527 15.4%  
From Investments Rs m-224-2,148 10.4%  
From Financial Activity Rs m-27-1,024 2.6%  
Net Cashflow Rs m-15-1,646 0.9%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 7.9 2.5%  
FIIs % 9.7 0.1 9,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.1 152.6%  
Shareholders   54,701 18,270 299.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS